Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Community Health

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    167 result(s) found for: Community Health. Displaying page 1 of 9.
    1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2015-001239-19 Sponsor Protocol Number: PHRN14-PFD-CAPE_COD Start Date*: 2015-08-14
    Sponsor Name:CHRU de TOURS
    Full Title: Effects of low-dose corticosteroids on survival of severe Community-Acquired Pneumonia
    Medical condition: Severe community-acquired pneumonia
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-002871-15 Sponsor Protocol Number: V58P13 Start Date*: 2007-09-14
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase III, Randomized, Observer-Blind, Placebo-Controlled, Multicenter Study to Assess Clinical Efficacy of a Cell-Derived Subunit Influenza Vaccine and an Egg-Derived Subunit Influenza Vaccine i...
    Medical condition: Influenza disease.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2010-022380-35 Sponsor Protocol Number: 982 Start Date*: 2011-06-10
    Sponsor Name:Biotest AG
    Full Title: A randomized, double-blind, placebo-controlled, multicenter, parallel-group, adaptive group-sequential phase II study, to determine the efficacy and safety of BT086 as an adjunctive treatment in ...
    Medical condition: severe Community Acquired Pneumonia (sCAP)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006951-32 Sponsor Protocol Number: REP0321 Start Date*: 2022-04-05
    Sponsor Name:Dompé farmaceutici s.p.a.
    Full Title: Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multina...
    Medical condition: COVID-19 and other community-acquired pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) IT (Ongoing) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004071-13 Sponsor Protocol Number: PTK0796-CABP-1200 Start Date*: 2015-05-20
    Sponsor Name:Paratek Pharma LLC
    Full Title: A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects with Community-Acquired Bacterial P...
    Medical condition: Community-Acquired Bacterial Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) CZ (Completed) LV (Completed) DE (Completed) ES (Completed) BE (Completed) PL (Prematurely Ended) GR (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2011-002177-34 Sponsor Protocol Number: 10 150 02 Start Date*: 2013-11-07
    Sponsor Name:CHU de Toulouse
    Full Title: Population pharmacokinetics of levofloxacin in intensive care patients with severe community-acquired pneumonia
    Medical condition: community-acquired pneumonia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10032502 Other specified alveolar and parietoalveolar pneumopathies LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003244-27 Sponsor Protocol Number: PANORAMIC-Norway Start Date*: 2023-04-11
    Sponsor Name:Helse Bergen HF
    Full Title: PAxlovid loNg cOvid-19 pRevention triAl with recruitMent In the Community in Norwayy
    Medical condition: COVID-19 SARS-CoV-2
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004848 10084355 COVID-19 virus test positive LLT
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000736-37 Sponsor Protocol Number: 1001 Start Date*: 2022-08-12
    Sponsor Name:Biotest AG
    Full Title: A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with CAP including COVID-19 pneu...
    Medical condition: non-severe community-acquired pneumonia (CAP) or moderate or severe Coronavirus Disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10084380 COVID-19 pneumonia PT
    20.1 10021881 - Infections and infestations 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) ES (Prematurely Ended) HU (Completed) AT (Ongoing) BE (Ongoing) LV (Ongoing) LT (Ongoing) PT (Ongoing) SK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003444-37 Sponsor Protocol Number: ENTERR06929 Start Date*: 2016-08-26
    Sponsor Name:Sanofi
    Full Title: Bacillus clausii in the treatment of acute community–acquired diarrhea among Latin American children (cadiLAc)
    Medical condition: Diarrhea
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004856 10000706 Acute diarrhea LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-001873-10 Sponsor Protocol Number: P160929J Start Date*: 2020-04-03
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Full Title: ANTIBIOTIC THERAPY IN RESPIRATORY TRACT INFECTIONS: AIR. A controlled randomized, open label, multicenter, non-inferiority trial evaluating an individualized antibiotic duration treatment strategy ...
    Medical condition: Community acquired pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002120-14 Sponsor Protocol Number: 3074K4-2207-WW Start Date*: 2008-10-29
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceutical Inc.
    Full Title: A Multicenter, Open-Label, Ascending Multiple-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age With Selected Serious Infections
    Medical condition: Complicated intra-abdominal infections (cIAI), complicated skin and skin structure infections (cSSSI), community-acquired pneumonia (CAP).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056570 Intra-abdominal infection LLT
    9.1 10040872 Skin infection LLT
    9.1 10010120 Community acquired pneumonia LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004039-37 Sponsor Protocol Number: CE01-203 Start Date*: 2014-10-10
    Sponsor Name:Cempra Pharmaceuticals, Inc.
    Full Title: A Phase 2/3, Randomised, Partly blinded (blinded investigator), Multi-center, Comparative Study to Determine the Safety and activity of Solithromycin (Intravenous and oral) in paediatric patients ...
    Medical condition: suspected or confirmed community acquired bacterial pneuumonia (CABP)
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA GB (Completed) HU (Completed) ES (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2012-002203-18 Sponsor Protocol Number: P903-31 Start Date*: 2012-07-18
    Sponsor Name:Cerexa, Inc. (subsidary of Forest Laboratories)
    Full Title: A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone in Pediatric Subjects With...
    Medical condition: Community-acquired Bacterial Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10035664 Pneumonia PT
    14.1 10021881 - Infections and infestations 10004051 Bacterial pneumonia, unspecified LLT
    14.1 10021881 - Infections and infestations 10060946 Pneumonia bacterial PT
    14.1 10021881 - Infections and infestations 10010120 Community acquired pneumonia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA HU (Completed) GR (Completed) ES (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-003628-29 Sponsor Protocol Number: REGC-15-035.R1 Start Date*: 2015-12-01
    Sponsor Name:University of Brighton
    Full Title: The introduction and use of Entonox as an alternative method of pain relief for intrauterine contraception device insertions.
    Medical condition: This study is to investigate the efficacy of 2 methods of pain relief during the procedure of an intrauterine contraceptive device insertion (coil). There is no medical condition or disease under i...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-001731-55 Sponsor Protocol Number: 106636 Start Date*: 2007-08-09
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III/IV, community-randomized, controlled study to evaluate the effectiveness of two vaccination strategies using GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine in reducing the p...
    Medical condition: For the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus (HPV) types 16 and 18.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10008230 Cervix neoplasms malignant HLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2011-004425-27 Sponsor Protocol Number: 5863 Start Date*: 2012-05-29
    Sponsor Name:Newcastle Upon Tyne Hospitals NHS Foundation Trust
    Full Title: Study of Optimal Replacement of Thyroxine in the ElDerly (SORTED) SORTED 1 – a Randomised Controlled Trial (Pilot study) SORTED 2 – Qualitative Interviews SORTED 3 – Retrospective Cohort
    Medical condition: hypothyroidism (elderly individuals)
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-002612-25 Sponsor Protocol Number: versie 2 Start Date*: 2007-09-14
    Sponsor Name:St. Antonius Hospital
    Full Title: Dexamethasone infusion in community-acquired pneumonia
    Medical condition: pneumonia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10035664 Pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003932-35 Sponsor Protocol Number: BIO101-CL03 Start Date*: 2018-02-20
    Sponsor Name:Biophytis S.A.
    Full Title: Safety and Efficacy of BIO-101 175 mg b.i.d. and 350 mg b.i.d. 26-week oral administration to patients suffering from age-related SARcopenia, including sarcopenic obesity, Aged ≥65 years and at ris...
    Medical condition: Sarcopenia including sarcopenic obesity
    Disease: Version SOC Term Classification Code Term Level
    20.1 10028395 - Musculoskeletal and connective tissue disorders 10063024 Sarcopenia PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001637-41 Sponsor Protocol Number: A7801001 Start Date*: 2005-07-26
    Sponsor Name:Pfizer Consumer Healthcare cva/sca
    Full Title: A community pharmacy based investigation in the self-medication area Efficacy and safety of Sinutab® (Paracetamol (500mg)/Pseudoephedrine (30mg)) on subjects with nasal congestion accompanied by h...
    Medical condition: Medical rationale= Investigation of combination drug Sinutab in symptomatic relief of common cold with nasal symptoms. Community pharmacists are considered as local investigators including subjec...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000058-35 Sponsor Protocol Number: A7801002 Start Date*: 2006-04-26
    Sponsor Name:Pfizer Consumer Healthcare Comm. VA/SCA
    Full Title: A community pharmacy based investigation in the self-medication area Efficacy and safety of Sinutab® [Paracetamol (500mg) and Pseudoephedrine (30mg)] on subjects with nasal congestion accompanied ...
    Medical condition: The medical rationale = to investigate this combination drug in the symptomatic relief of common cold with nasal symptoms. The reduction of symptom severity may allow subjects receiving active medi...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:28:43 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA